CHF Solutions Inc. (NASDAQ:CHFS) and Ra Medical Systems Inc. (NYSE:RMED) compete with each other in the Medical Appliances & Equipment sector. We will analyze and compare their risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CHF Solutions Inc.	4.33M	1.00	28.65M	-14.45	0.00
Ra Medical Systems Inc.	6.21M	13.97	18.99M	-1.65	0.00

In table 1 we can see CHF Solutions Inc. and Ra Medical Systems Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 shows us CHF Solutions Inc. and Ra Medical Systems Inc.’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CHF Solutions Inc.	-661.66%	-267.6%	-226.7%
Ra Medical Systems Inc.	-305.80%	0%	0%

Liquidity

CHF Solutions Inc.’s Current Ratio is 5.6 while its Quick Ratio is 4.6. On the competitive side is, Ra Medical Systems Inc. which has a 2 Current Ratio and a 1.8 Quick Ratio. CHF Solutions Inc. is better positioned to pay off short and long-term obligations compared to Ra Medical Systems Inc.

Insider & Institutional Ownership

Institutional investors held 19.4% of CHF Solutions Inc. shares and 34.4% of Ra Medical Systems Inc. shares. Insiders held 0.4% of CHF Solutions Inc. shares. Comparatively, Ra Medical Systems Inc. has 28% of it’s share held by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
CHF Solutions Inc.	-20.9%	-35.78%	-44.44%	-74.36%	-77.35%	-79.77%
Ra Medical Systems Inc.	-11.6%	-9.33%	0%	0%	0%	-55.8%

For the past year Ra Medical Systems Inc. has weaker performance than CHF Solutions Inc.

Summary

On 9 of the 10 factors Ra Medical Systems Inc. beats CHF Solutions Inc.

CHF Solutions, Inc., an early-stage medical device company, develops cardiac and coronary disease products primarily in the United States. It focused on commercializing the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. The company was formerly known as Sunshine Heart, Inc. and changed its name to CHF Solutions, Inc. in May 2017. CHF Solutions, Inc. was founded in 1999 and is based in Eden Prairie, Minnesota.